BD 311
Alternative Names: BD311; Integration-deficient lentiviral vector expressing VEGFA antibody - Shanghai BDGeneLatest Information Update: 28 Nov 2024
Price :
$50 *
At a glance
- Originator Shanghai BDgene
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action Gene transference; Vascular endothelial growth factor replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Eye disorders
Most Recent Events
- 28 Nov 2024 No recent reports of development identified for phase-I development in Eye-disorders(In the elderly, Treatment-experienced, In adults) in China (Intravitreous, Injection)
- 29 Oct 2021 Phase-I clinical trials in Eye disorders (In adults, In the elderly, Treatment-experienced) in China (Ophthalmic) (NCT05099094)